Pharmaceuticals News

Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product salesQUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured TORONTO,...

ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint Inhibitor (ICI) Therapy AACR...

WATERTOWN, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with...

HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics,...

Announced recent Investigational New Drug (IND) submission to the FDA for CUE-221 in food allergy applicationsCompleted a $50 million private placement (PIPE) to further fund clinical development and...

ZUG, Switzerland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company. Attachments ...

EMERYVILLE, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

CAMBRIDGE, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform...

On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Expected in...

60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results